On May 2, 2026, the World Health Organization announced the prequalification of Coartem Baby, the first malaria drug specifically designed for infants.
This approval signifies a major public health milestone, enabling healthcare providers to treat newborns with malaria more safely, rather than relying on medications intended for older children.
The introduction of Coartem Baby is expected to improve health outcomes for vulnerable populations, particularly in regions heavily impacted by malaria.